NASDAQ:SLRX

Salarius Pharmaceuticals (SLRX) Stock Forecast, Price & News

$1.49

-0.01 (-0.67%)

(As of 05/26/2023 08:47 PM ET)

Compare

Today's Range: $1.44
▼
$1.50
50-Day Range: $1.37
▼
$2.16
52-Week Range: $1.07
▼
$7.20

Volume: 16,400 shs
Average Volume: 159,608 shs
Market Capitalization: $3.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Salarius Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
4.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.70) to ($4.63) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Salarius Pharmaceuticals.

5.0

Short Interest

Percentage of Shares Shorted
4.15% of the float of Salarius Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Salarius Pharmaceuticals has recently decreased by 16.05%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Salarius Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Salarius Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLRX.

4.1

News and Social Media Coverage

News Sentiment
Salarius Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Salarius Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
9 people have searched for SLRX on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
MarketBeat Follows
4 people have added Salarius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.30% of the stock of Salarius Pharmaceuticals is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Salarius Pharmaceuticals are expected to grow in the coming year, from ($5.70) to ($4.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Salarius Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Salarius Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Salarius Pharmaceuticals has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Salarius Pharmaceuticals (NASDAQ:SLRX) Stock

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Receive SLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SLRX Stock News Headlines

May 17, 2023 | marketwatch.com

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 16, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 29, 2023 | Behind the Markets (Ad)

Is This The End Of Your Retirement?

Soon, the U.S. Government is going to make an announcement that could radically alter your retirement. Two of America's largest banks - Goldman Sachs and J.P. Morgan - have quietly warned their richest clients to prepare for it. The clock is ticking. Find out How to Protect Yourself from the Greatest Crisis Facing Retirees in 70 Years before it's too late.

May 12, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 11, 2023 | msn.com

Recap: Salarius Pharmaceuticals Q1 Earnings

May 11, 2023 | finanznachrichten.de

Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023 | americanbankingnews.com

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) to Post Q1 2023 Earnings of ($1.30) Per Share, Zacks Small Cap Forecasts

May 29, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser

Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>

May 9, 2023 | msn.com

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

May 9, 2023 | finance.yahoo.com

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 2, 2023 | uk.finance.yahoo.com

Salarius Pharmaceuticals, Inc. (SLRX)

May 1, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

April 24, 2023 | msn.com

Salarius Pharmaceuticals (FRA:FP1) Price Target Decreased by 7.80% to 55.93

April 20, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

April 4, 2023 | finance.yahoo.com

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

April 4, 2023 | finance.yahoo.com

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023

April 1, 2023 | americanbankingnews.com

Diamond Equity Weighs in on Salarius Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:SLRX)

March 31, 2023 | americanbankingnews.com

Salarius Pharmaceuticals, Inc. to Post FY2023 Earnings of ($10.27) Per Share, Diamond Equity Forecasts (NASDAQ:SLRX)

March 29, 2023 | americanbankingnews.com

Salarius Pharmaceuticals (NASDAQ:SLRX) Posts Quarterly Earnings Results, Misses Expectations By $0.67 EPS

March 27, 2023 | finanznachrichten.de

Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 27, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 15, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

March 7, 2023 | finance.yahoo.com

Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia

February 16, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

January 27, 2023 | finance.yahoo.com

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

January 22, 2023 | morningstar.com

Thinking about buying stock in Salarius Pharmaceuticals, Appharvest, Ally Financial, Jaguar Health, or IONQ?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SLRX Company Calendar

Last Earnings: 3/27/2023
Today: 5/29/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SLRX
CUSIP: N/A
CIK: 1615219
Web: www.salariuspharma.com
Phone: (832) 834-6992
Fax: N/A
Employees: 16
Year Founded: 2011

Profitability

EPS (Most Recent Fiscal Year): ($13.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,610,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -138.54%
Return on Assets: -112.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.21
Quick Ratio: 2.21

Sales & Book Value

Annual Sales: $1.84 million
Price / Sales: 2.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.23 per share
Price / Book: 0.67

Miscellaneous

Outstanding Shares: 2,490,000
Free Float: 2,434,000
Market Cap: $3.71 million
Optionable: Not Optionable
Beta: 0.96

Social Links

Key Executives

David J. Arthur
President, Chief Executive Officer & Director

Mark J. Rosenblum
Chief Financial Officer & Executive Vice President

Nadeem Q. Mirza
Senior Vice President-Clinical Development

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

SLRX Stock - Frequently Asked Questions

How have SLRX shares performed in 2023?: Salarius Pharmaceuticals' stock was trading at $1.53 on January 1st, 2023. Since then, SLRX shares have decreased by 2.6% and is now trading at $1.49.
View the best growth stocks for 2023 here.
Are investors shorting Salarius Pharmaceuticals?: Salarius Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 94,700 shares, a decrease of 16.0% from the April 30th total of 112,800 shares. Based on an average daily volume of 92,600 shares, the short-interest ratio is currently 1.0 days. Currently, 4.2% of the shares of the company are short sold.
View Salarius Pharmaceuticals' Short Interest.
When is Salarius Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our SLRX earnings forecast.
How were Salarius Pharmaceuticals' earnings last quarter?: Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announced its earnings results on Monday, March, 27th. The company reported ($2.83) EPS for the quarter, missing analysts' consensus estimates of ($2.16) by $0.67.
What ETF holds Salarius Pharmaceuticals' stock ?: Horizon Kinetics Medical ETF holds 32,400 shares of SLRX stock, representing 0.25% of its portfolio.
When did Salarius Pharmaceuticals' stock split?: Salarius Pharmaceuticals's stock reverse split on Monday, October 17th 2022. The 1-25 reverse split was announced on Monday, October 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Salarius Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).
What is Salarius Pharmaceuticals' stock symbol?: Salarius Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLRX."
How do I buy shares of Salarius Pharmaceuticals?: Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Salarius Pharmaceuticals' stock price today?: One share of SLRX stock can currently be purchased for approximately $1.49.
How much money does Salarius Pharmaceuticals make?: Salarius Pharmaceuticals (NASDAQ:SLRX) has a market capitalization of $3.71 million and generates $1.84 million in revenue each year. The company earns $-31,610,000.00 in net income (profit) each year or ($13.72) on an earnings per share basis.
How can I contact Salarius Pharmaceuticals?: Salarius Pharmaceuticals' mailing address is 2450 Holcombe Blvd. Suite X, Houston TX, 77021. The official website for the company is www.salariuspharma.com. The company can be reached via phone at (832) 834-6992 or via email at jeremy@lifesciadvisors.com.

This page (NASDAQ:SLRX) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial